Protocol Ledger

NCT07195695 · Phase III · RECRUITING

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Interventional Phase III clinical trial protocol NCT07195695 sponsored by Boehringer Ingelheim in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-16 Enrollment: 400 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07195695
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)400 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07195695
Protocol FieldVerified Registry Value
NCT IdentifierNCT07195695
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment400 participants (ESTIMATED)
Registered Start Date2026-01-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI